USA grants patent nod to Dei BioPharma cancer breakthroughs

On July 21, the United States Patent and Trademark Office (USPTO) accepted two patent applications from Dei BioPharma, a Ugandan biotechnology company led by Dr Matthias Magoola—a homegrown scientist whose work could rewrite the future of cancer treatment and immune disease care.

But these are not just medical breakthroughs. For many, they signal something more personal: the possibility that life-saving innovation can finally reach those who need it most—not just in Boston or Berlin, but in Busia, Mbale, or Mumbai.

A NEW KIND OF CANCER VACCINE

The first of the two patents is for a universal mRNA cancer vaccine—an approach that could leapfrog some of the most stubborn limitations in cancer immunotherapy today.

Unlike traditional cancer vaccines, which must be custom-built for individual patients based on their tumor type, Magoola’s vaccine uses generalized antigens—molecular signals the body recognizes as foreign—wrapped in lipid nanoparticles that kickstart a type-I interferon response.

In simple terms, it flips a molecular switch that makes invisible tumors visible to the immune system.

“It’s like turning on a spotlight in a dark room,” says a source close to the preclinical trial team. “Once the immune system can see the cancer, it knows how to fight it.” Early preclinical trials have been promising. Mice with solid tumors showed complete tumor regression, with up to 90 per cent protection against recurrence.

The vaccine also appears to work in tandem with checkpoint inhibitors— a class of drugs that includes anti-PD-1 therapies—making the immune attack more durable and comprehensive. The vaccine’s ability to induce “epitope spreading” means it trains the immune system to recognize multiple tumor markers—not just one.

This could prove crucial in treating cancers that mutate quickly or resist first-line therapies. The second patent application focuses on something equally groundbreaking: a single-chain variable fragment (scFv) biologic that targets IL-23p19, a cytokine implicated in chronic inflammatory diseases like psoriasis, Crohn’s disease, and certain types of arthritis.

Big pharmaceutical companies currently dominate this space with expensive monoclonal antibody drugs like Skyrizi® and Tremfya®, which can cost tens of thousands of dollars per year. But Magoola’s scFv is different—not only in design but in philosophy. Smaller than traditional antibodies and engineered to bind more efficiently to its target, the biologic is also fused with proteins like albumin or transferrin, giving it a longer half-life and better tissue penetration.

Most importantly, it can be delivered in non-invasive formats—through inhalers, nasal sprays, skin patches, or even topical creams. That could be a game-changer for patients in under-resourced settings where cold-chain storage or infusion clinics are out of reach.

By using microbial systems instead of mammalian cells, the cost of production drops by as much as 80 percent, making it one of the most affordable biologics in development today.

“THIS IS THE FUTURE OF MEDICINE”

For Dr Magoola, the significance of these patents goes beyond the science. “These patents are not just scientific achievements,” he told reporters.

“They are moral declarations. We are abolishing the myth that cures belong only to the rich.” A former academic turned entrepreneur, Magoola founded Dei BioPharma to build a pipeline of low-cost, high-impact therapeutics and vaccines—created in Africa, for Africa, and the world.

His innovations have already earned him Uganda’s “Faces of Science” national award in June, a rare nod to homegrown excellence in pharmaceutical research. Still, his eyes remain firmly set on global transformation.

“The future of medicine must be globally accessible, scientifically credible, and deeply human,” he said. “That’s what we are building at Dei BioPharma.”

WHY THIS MATTERS 

The World Health Organization estimates that only 15 per cent of patients in low-income countries who need cancer treatment actually receive it. The reasons are manifold: limited infrastructure, costly therapies, and the complexity of delivering biologic drugs in settings with poor logistics. Magoola’s work addresses all three.

By simplifying how advanced therapies are made, stored, and administered, Dei BioPharma is pushing the boundaries of pharmaceutical equity—not as charity, but as a sustainable, scalable model for innovation.

If these therapies prove successful in clinical trials, Uganda could become a global reference point for biotech leadership in the Global South, challenging the status quo where medical innovation flows almost exclusively from the North to the South.

A LONG ROAD AHEAD

Of course, patents are only the beginning. Clinical trials, regulatory approvals, and market access still lie ahead. But the foundation is solid—and the vision bold.

If successful, Dei BioPharma’s platforms could offer a universal cancer vaccine that doesn’t require personalised sequencing, and a mass-market immune therapy that doesn’t require cold storage or specialist infusion.

That is not just science. That is a shift in power. And perhaps, in the quiet labs of Kampala, a preview of what the future of global health might finally look like: decentralized, affordable, and fair.

Related